Efficacy of using a standard activity of 131I-MIBG therapy in patients with disseminated neuroendocrine tumours
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The aim of this analysis was to evaluate the response to standard activity of 131I-meta-iodobenzylguanidine (MIBG) in patients with disseminated neuroendocrine tumours (NETs), comparing overall survival of patients with symptomatic response, tumour size (as assessed by CT) and relevant plasma tumour markers.
A retrospective review of patients who had undergone 131I-MIBG treatment between March 2001 and December 2006 was carried out. The administered activity of 131I-MIBG was 5.5 GBq (NETs) and 7 GBq (phaeochromocytoma). Three cycles of treatment were planned with an interval of 10–12 weeks. A pre-therapy scan with 123I-MIBG was performed to ascertain appropriate biodistribution.
Thirty-eight patients were identified. Only two patients developed significant bone marrow suppression. Symptomatic response: data were available in 37 of 38 patients: 15 patients had improved symptoms, 19 had no improvement in symptoms and 3 were asymptomatic. In those with a symptomatic response, the median overall survival was 58 months vs no response of 20.0 months (p = 0.001). CT response: in those with stable disease, the median overall survival was 58 months compared with progressive disease of 16.0 months. The difference between these groups was significant (p = 0.006). Hormonal response: this was available in only 20 of 38 patients. The median overall survival was the same for patients that had increased hormone levels and patients that had stable/decreased hormone levels (48 months).
Standard activity 131I-MIBG is well tolerated. Symptomatic response to treatment is a significant predictor of overall survival. Whilst CT response also appears to predict survival, hormonal levels do not appear to correlate with survival.
- Wieland DM, Swanson DP, Brown LE, Beierwaltes WH. Imaging the adrenal medulla with an I-131-labeled antiadrenergic agent. J Nucl Med 1979;20:155–8.
- Wafelman AR, Hoefnagel CA, Maes RA, Beijnen JH. Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med 1994;21:545–59. CrossRef
- Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 2001;86:895–902. CrossRef
- Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36:228–47. CrossRef
- Quigley AM, Buscombe JR, Shah T, Gnanasegaran G, Roberts D, Caplin ME, et al. Intertumoural variability in functional imaging within patients suffering from neuroendocrine tumours. An observational, cross-sectional study. Neuroendocrinology 2005;82(3–4):215–20. CrossRef
- McEwan AJ, Shapiro B, Sisson JC, Bierwaltes WH, Ackery DM. Radio-iodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors. Semin Nucl Med 1985;15:132–53. CrossRef
- Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur J Nucl Med 1994;21:561–81.
- Loh KC, Fitzgerald PA, Matthy KK, Yeo PPB, Price DC. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 1997;20:648–58.
- Buscombe JR, Cwikla JB, Caplin ME, Hilson AJ. Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response. Nucl Med Commun 2005;26:969–76. CrossRef
- Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman J, Onaitis MW, et al. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer 2004;101(9):1987–93. CrossRef
- Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H, Beijnen JH. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol 1996;14:1829–38.
- Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with 131I-metaiodobenzylguanidine (131I-mIBG). Clin Endocrinol (Oxf) 2001;55:47–60. CrossRef
- Bomanji J, Britton KE, Ur E, Hawkins L, Grossman AB, Besser GM. Treatment of malignant phaeochromocytoma, paraganglioma and carcinoid tumours with 131I-metaiodobenzylguanidine. Nucl Med Commun 1993;14:856–61. CrossRef
- Nwosu AC, Jones L, Vora J, Poston GJ, Vinjamuri S, Pritchard DM. Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours. Br J Cancer 2008;98:1053–8. CrossRef
- Sywak MS, Pasieka JL, McEwan A, Kline G, Rorstad O. 131I-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors. World J Surg 2004;28:1157–62. CrossRef
- Giovanella LC. Chromogranin A: a circulating neuroendocrine marker—biology, pathology, assay technology and clinical applications. Cisbio www.ria-cis.com/ressources/produits/00370%20CIS%20CHROMOGRANIN%20GB.pdf
- Fielding SL, Flower MA, Ackery D, Kemshead JT, Lashford LS, Lewis I. Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study. Eur J Nucl Med 1991;18:308–16. CrossRef
- Monsieurs M, Brans B, Bacher K, Dierckx R, Thierens H. Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans. Eur J Nucl Med Mol Imaging 2002;29(12):1581–7. CrossRef
- Modlin IM, Latich I, Zikusoka M, Kidd M, Eick G, Chan AK. Gastrointestinal carcinoids: the evolution of diagnostic strategies. J Clin Gastroenterol 2006;40:572–82. CrossRef
- Paganelli G, Bodei L, Handkiewicz Junak D, Rocca P, Papi S, Lopera Sierra M, et al. 90Y-DOTA-D-Phe1-Tyr3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 2002;66:393–8. CrossRef
- Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124–30. CrossRef
- Madsen M, Bushnell D, Juweid ME, Menda Y, O’Dorisio MS, O’Dorisio T, et al. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model. J Nucl Med 2006;47:660–7.
- Efficacy of using a standard activity of 131I-MIBG therapy in patients with disseminated neuroendocrine tumours
European Journal of Nuclear Medicine and Molecular Imaging
Volume 37, Issue 5 , pp 904-912
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Neuroendocrine tumours
- 131I-MIBG (meta-iodobenzylguanidine)
- Industry Sectors